FDA greenlights BD’s rapid diagnostic HPV test: 3 things to know

The FDA on Tuesday granted premarket approval to BD’s Onclarity HPV Assay.

Advertisement

Here are three things to know.

1. The test, performed on the BD Viper LT system, can detect 14 types of HPV from patient specimens collected for cervical cancer screening or from a Pap smear.

2. The assay can also pinpoint HPV genotypes 16, 18 and 45, which are linked to a majority of cervical cancers.

3. In the future, BD hopes to achieve additional regulatory approvals to use the assay on other HPV types.

More articles on supply chain:
Amazon pushes to become a major hospital supplier: 7 things to know
White House advisers propose fast-tracking reviews of brand-name drugs to lower costs: 6 things to know
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know

Advertisement

Next Up in Supply Chain

  • Medline is laying off 304 workers, according to a notice filed with the state of Illinois and a Nov. 5…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.